Skip to content

Safety and Effectiveness of Aquamid as Compared to Restylane for the Aesthetic Treatment of Nasolabial Folds

A Double-Masked, Randomized, Multi-Center, 2-Arm Parallel Study Comparing the Safety and Effectiveness of Aquamid and Restylane for the Aesthetic Treatment of Nasolabial Folds

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00407914
Enrollment
315
Registered
2006-12-05
Start date
2006-12-31
Completion date
2009-07-31
Last updated
2009-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial Wrinkles

Keywords

wrinkles, soft tissue filler, Aquamid

Brief summary

The purpose of this study is to compare the effectiveness of Aquamid and Restylane in aesthetically enhancing nasolabial folds 6 months after treatment and to evaluate the safety of Aquamid through 12 months after treatment. The study includes an extended follow up to 24 months.

Interventions

DEVICEAquamid

Subcutaneous injection

DEVICERestylane

Injection in dermis

Sponsors

Contura
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* interested on soft tissue augmentation for the nasolabial folds * moderate to severe nasolabial fold

Exclusion criteria

* sensitivity to anesthetics * allergy to hyaluronic acid * previous treatment with permanent fillers in the treated area * recent previous aesthetic procedure in the treatment area * infected skin areas or autoimmune diseases affecting the skin

Design outcomes

Primary

MeasureTime frame
Wrinkle Assessment ScaleBaseline, 3, 6, 9, 12 Months
Adverse device effectscontinuosly

Secondary

MeasureTime frame
Global Aesthetic Improvement ScaleOptimal treatment, 3, 6, 9 and 12 Months
Injection site reactionsAfter injection
Adverse eventscontinuosly

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026